These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37940761)

  • 1. EML4-ALK fusion protein in Lung cancer cells enhances venous thrombogenicity through the pERK1/2-AP-1-tissue factor axis.
    Su Y; Yi J; Zhang Y; Leng D; Huang X; Shi X; Zhang Y
    J Thromb Thrombolysis; 2024 Jan; 57(1):67-81. PubMed ID: 37940761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation.
    Li Y; Li Y; Zhang H; Shi R; Zhang Z; Liu H; Chen J
    BMC Pulm Med; 2021 Jun; 21(1):190. PubMed ID: 34090412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells.
    Tanizaki J; Okamoto I; Takezawa K; Sakai K; Azuma K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Janne PA; Nakagawa K
    Br J Cancer; 2012 Feb; 106(4):763-7. PubMed ID: 22240786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement.
    Kwon JH; Kim KJ; Sung JH; Suh KJ; Lee JY; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Bang SM; Kim S; Yoon SS; Lee JS
    Cells; 2019 Nov; 8(12):. PubMed ID: 31795298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
    Bokhari AA; Lai WY; Le AT; Gabre JL; Chuang TP; Fransson S; Bergman B; Djos A; Chen N; Martinsson T; Van den Eynden J; Doebele RC; Palmer RH; Hallberg B; Umapathy G
    Lung Cancer; 2022 Sep; 171():103-114. PubMed ID: 35933914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.
    Sun Y; Nowak KA; Zaorsky NG; Winchester CL; Dalal K; Giacalone NJ; Liu N; Werner-Wasik M; Wasik MA; Dicker AP; Lu B
    Mol Cancer Ther; 2013 May; 12(5):696-704. PubMed ID: 23443800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
    Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC
    J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing.
    Moskalev EA; Frohnauer J; Merkelbach-Bruse S; Schildhaus HU; Dimmler A; Schubert T; Boltze C; König H; Fuchs F; Sirbu H; Rieker RJ; Agaimy A; Hartmann A; Haller F
    Lung Cancer; 2014 Jun; 84(3):215-21. PubMed ID: 24674157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors.
    Li Y; Ye X; Liu J; Zha J; Pei L
    Neoplasia; 2011 Jan; 13(1):1-11. PubMed ID: 21245935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitive detection of EML4-ALK fusion oncoprotein of lung cancer by in situ proximity ligation assay.
    Rho JK; Lee H; Park CS; Choi CM; Lee JC
    Clin Chem Lab Med; 2013 Sep; 51(9):1843-8. PubMed ID: 23612660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.
    Takezawa K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
    Clin Cancer Res; 2011 Apr; 17(8):2140-8. PubMed ID: 21415216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
    Tanizaki J; Okamoto I; Okabe T; Sakai K; Tanaka K; Hayashi H; Kaneda H; Takezawa K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Nakagawa K
    Clin Cancer Res; 2012 Nov; 18(22):6219-26. PubMed ID: 22843788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy.
    Kanaji N; Bandoh S; Ishii T; Tadokoro A; Watanabe N; Takahama T; Haba R; Imataki O; Dobashi H; Matsunaga T
    Lung Cancer; 2012 Aug; 77(2):293-8. PubMed ID: 22494566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
    Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
    Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC.
    Dai Y; Wei Q; Schwager C; Hanne J; Zhou C; Herfarth K; Rieken S; Lipson KE; Debus J; Abdollahi A
    Radiat Oncol; 2018 Jan; 13(1):1. PubMed ID: 29304828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
    Zhang SS; Nagasaka M; Zhu VW; Ou SI
    Lung Cancer; 2021 Aug; 158():126-136. PubMed ID: 34175504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
    Tao H; Shi L; Zhou A; Li H; Gai F; Huang Z; Che N; Liu Z
    Lung Cancer; 2020 Nov; 149():154-161. PubMed ID: 33017727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EML4-ALK induces epithelial-mesenchymal transition consistent with cancer stem cell properties in H1299 non-small cell lung cancer cells.
    Guo F; Liu X; Qing Q; Sang Y; Feng C; Li X; Jiang L; Su P; Wang Y
    Biochem Biophys Res Commun; 2015 Apr; 459(3):398-404. PubMed ID: 25735977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
    Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
    Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
    J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.